These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1156 related items for PubMed ID: 14564311

  • 1. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR, Sperling RS, Reicin A, Gertz BJ.
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
    Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ.
    Circulation; 2001 Nov 06; 104(19):2280-8. PubMed ID: 11696466
    [Abstract] [Full Text] [Related]

  • 3. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
    Tuleja E, Mejza F, Cmiel A, Szczeklik A.
    Arterioscler Thromb Vasc Biol; 2003 Jun 01; 23(6):1111-5. PubMed ID: 12730088
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 01; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 5. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E, Waldman SA.
    J Clin Pharmacol; 2000 Dec 01; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
    Peretz A.
    Rev Med Brux; 2001 Sep 01; 22(4):A377-80. PubMed ID: 11680204
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
    Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q.
    Am J Cardiol; 2002 Jan 15; 89(2):204-9. PubMed ID: 11792343
    [Abstract] [Full Text] [Related]

  • 10. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
    Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, Bertrand F, Dagenais GR.
    Circulation; 2004 Aug 24; 110(8):934-9. PubMed ID: 15302800
    [Abstract] [Full Text] [Related]

  • 11. COX-1 and COX-2 inhibitors.
    Hawkey CJ.
    Best Pract Res Clin Gastroenterol; 2001 Oct 24; 15(5):801-20. PubMed ID: 11566042
    [Abstract] [Full Text] [Related]

  • 12. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 24; 8(15 Suppl):S401-13. PubMed ID: 12416790
    [Abstract] [Full Text] [Related]

  • 13. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
    Gertz BJ, Krupa D, Bolognese JA, Sperling RS, Reicin A.
    Curr Med Res Opin; 2002 Oct 24; 18(2):82-91. PubMed ID: 12017215
    [Abstract] [Full Text] [Related]

  • 14. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 24; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

  • 15. Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.
    Ahuja N, Singh A, Singh B.
    J Pharm Pharmacol; 2003 Jul 24; 55(7):859-94. PubMed ID: 12906745
    [Abstract] [Full Text] [Related]

  • 16. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC.
    Clin Exp Rheumatol; 2001 Jul 24; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [Abstract] [Full Text] [Related]

  • 17. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ, Alzheimer's Disease Cooperative Study.
    JAMA; 2003 Jun 04; 289(21):2819-26. PubMed ID: 12783912
    [Abstract] [Full Text] [Related]

  • 18. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA, Weir MR.
    Cleve Clin J Med; 2002 Jun 04; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [Abstract] [Full Text] [Related]

  • 19. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 20. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A, Krahn M, Naglie G.
    Arthritis Rheum; 2003 Jun 15; 49(3):283-92. PubMed ID: 12794781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.